title: [Morphological characteristics of the macula in patients with retinal vein occlusion before and after the treatment: preliminary results].
abstract: The article presents examination results of 26 patients with macular edema (ME) due to retinal vein occlusion (RVO) before and 1 month after an intravitreal injection of ranibizumab (Lucentis). Besides routine assessment, retinal spectral-domain optical coherent tomography (OCT) was performed in all cases. In accordance with derived OCT patterns of macular edema the patients were devided into two groups: swelling of the inner and outer retinal layers with serous detachment of neuroepithelium (group 1) and intraretinal edema with pseudocysts (group 2). It is shown that initial OCT features of retina in patients with ME due to RVO are prognostic for treatment results (serous retinal detachment may serve as a preventing factor of photoreceptor damage) and that visual improvement in patients with ME and serous detachment of neuroepithelium anticipates morphological changes.
authors.forename: A A
authors.initials: AA
authors.lastname: Kazarian
authors.forename: A A
authors.initials: AA
authors.lastname: Burladinova
authors.forename: O A
authors.initials: OA
authors.lastname: Lebenkova
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000627:therapeutic use*; D018450:Disease Progression; D005260:Female; D005451:Fluorescein Angiography; D005500:Follow-Up Studies; D005654:Fundus Oculi; D006801:Humans; D058449:Intravitreal Injections; D008266:Macula Lutea / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D000069579:Ranibizumab; D012170:Retinal Vein Occlusion / Q000175:diagnosis* / Q000188:drug therapy; D012189:Retrospective Studies; D041623:Tomography, Optical Coherence / Q000379:methods*; D016896:Treatment Outcome
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000069579:Ranibizumab